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Abstract 
Background: Patients with angina‑like symptoms without myocardial perfusion scintigram (MPS)‑verified abnormality 
may still be at risk for cardiovascular events. We hypothesized that insulin resistance could play a role in this population 
even without diagnosed diabetes. We further explored physiological and blood biomarkers, as well as global gene expres‑
sion patterns that could be closely related to impaired glucose homeostasis to deepen our mechanistic understanding.
Methods: A total of 365 non‑diabetic patients with suspected myocardial ischemia referred to MPS were enrolled 
and followed up regarding event‑free survival with a median time of 5.1 years. All patients underwent endothelial 
function assessment by reactive hyperemic index (RHI) using EndoPAT and extensive biomarker analysis. Whole blood 
global gene expression pathway analysis was performed in a subset of patients.
Results: Homeostasis model assessment of insulin resistance (HOMA‑IR) added independent prognostic value in 
patients without myocardial perfusion defects. In a multivariable analysis, HOMA‑IR was inversely associated with low 
RHI. Furthermore, elevated HOMA‑IR was associated with decreased levels of vascular endothelial growth factor D, 
stem cell factor and endocan as well as to increased level of interleukin‑6. Global gene expression pathway analysis of 
whole blood cells showed that high HOMA‑IR and impaired endothelial function were associated with upregulated 
pro‑inflammatory pathways and down‑regulated eukaryotic initiation factor‑2 pathway.
Conclusions: Insulin resistance measured by HOMA‑IR is associated with endothelial dysfunction and confers 
independent prognostic information in non‑diabetic patients with chest pain without myocardial perfusion defects. 
Increased systemic pro‑inflammatory state and decreased levels of pro‑angiogenic vascular growth factors may be 
important underlying molecular mechanisms.
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Background
Myocardial ischemia has been shown to confer strong 
prognostic values in various patient populations [1, 2]. 
Traditionally obstructive, i.e., flow limiting coronary 
artery atherosclerosis has been in focus for coronary 
artery disease (CAD) management [3, 4]. However, the 
importance of non-obstructive CAD has gained increas-
ing attention since approximately 40–50  % of patients 
with stable angina have normal or near normal coronary 
arteries on coronary angiography [5, 6]. Despite the lack 
of obvious obstructive CAD, many of these patients are 
still at increased risk for future cardiovascular events [5, 
7]. Indeed, a recent study revealed high prevalence of 
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microvascular dysfunction in patients with chest pain 
and non-obstructive CAD [8].
Stress myocardial perfusion scintigram (MPS) is of 
strong prognostic value identifying hemodynamically 
significant obstructive CAD in patients with suspected 
myocardial ischemia [2]. A recent study suggests MPS to 
better assess functionally significant CAD compared to 
coronary angiography in patients with intermediate pre-
test probability [9]. However, since MPS provides rela-
tive flow distribution pattern rather than absolute flow, 
it might still be less sensitive to detect coronary micro-
vascular disease, including endothelial-dependent as well 
as independent coronary microvascular abnormalities 
in patients with chest pain and non-obstructive CAD 
[10]. Recently, we reported a role of assessing peripheral 
endothelial function in risk stratification of patients with 
chest pain without myocardial perfusion defects. This 
further indicates that other pathophysiological features 
than hemodynamically significant macrovascular disease 
may be responsible for clinical outcome of patients with 
angina-like symptoms [11].
Endothelial dysfunction is a consequence of different 
mechanisms causing impaired vasodilation or increased 
vasoconstriction [12, 13] leading to microvascular dys-
function [14]. In addition to endothelial dysfunction, 
the involvement of vascular remodeling, rarefaction 
and collaterals are important mechanisms [13], empha-
sizing its complexity. Microvascular dysfunction in the 
absence of obstructive CAD may be an early sign of 
cardiovascular risk. Consequently, understanding of 
associated mechanisms could be of great importance 
in management of cardiometabolic diseases. Diabetic 
patients are known to be at high risk for development 
of premature cardiovascular complications [15]. In 
fact, type 2 diabetes diagnosis is preceded by years of 
impaired glucose homeostasis, which may contribute to 
early pathological alteration in the cardiovascular sys-
tem. Pre-diabetes may cause functional [16, 17] as well 
as potentially structural vascular changes [18, 19], even-
tually leading to clinical manifestation of the underlying 
vascular diseases.
Cardiometabolic diseases may involve a complex 
chain of events including visceral adiposity, metabolic 
syndrome, Type 2 diabetes and CAD. In the present 
work we hypothesized that insulin resistance, assessed 
by homeostasis model assessment of insulin resistance 
(HOMA-IR), in non-diabetic patients is associated with 
peripheral endothelial dysfunction and worse clinical 
outcome in patients with chest pain without myocar-
dial perfusion defects. Further, for deepened mechanis-
tic understanding, we explored plasma protein and gene 




A total of 365 consecutive non-diabetic patients with 
chest pain referred to Sahlgrenska University Hospital 
in Gothenburg, Sweden due to suspected myocardial 
ischemia, were recruited to the study between 2006 and 
2008 (Fig. 1). At a separate occasion within 2 weeks fol-
lowing clinical MPS examination, all patients underwent 
examinations of peripheral endothelial function. Over-
night fasting blood samples were taken post examination 
of endothelial function. All patients underwent a stand-
ardized interview of medical history including history 
of diabetes, known CAD, smoking status and current 
cardiovascular medication. Patients with previous dia-
betes diagnosis, fasting plasma glucose ≥7.0 mmol/L or 
glycated haemoglobin A1c (HbA1c) level >48 mmol/mol 
were excluded from the study. Known CAD was defined 
as previous coronary artery bypass grafting, percuta-
neous coronary intervention or myocardial infarction 
(MI) and was collected from patients’ medical records. 
All participants provided written informed consent. The 
study complies with the declaration of Helsinki and was 
approved by the Local Ethics Committee at the Univer-
sity of Gothenburg.
Myocardial perfusion scintigram examination
Gated-SPECT studies were performed with a 2-day 
standard clinical protocol using 99mTc-sestamibi. Images 
were obtained using dual-head SPECT cameras (Infinia 
or Millennium VG, GE Healthcare, Milwaukee, Wiscon-
sin, USA). The severity of reversible myocardial ischemia 
was scored as no (score 0), mild (score 1), moderate (2) or 
severe (3). The extent was scored as none, small, medium 
or large (score 0 for no sign of ischemia, score 1 for 
<10 %, score 2 for 10–19 %, score 3 for >19 % of the entire 
myocardium being affected, respectively). No myocar-
dial perfusion defects was defined when both extent and 
severity of ischemia were scored 0.
Endothelial function measured by reactive hyperemic 
index
To determine peripheral endothelial function in this 
patient group we performed peripheral arterial tonom-
etry. The technician performing the examination was 
blinded to all clinical patient data including MPS results. 
Measurements were recorded using the EndoPAT2000 
device (Itamar Medical, Caesarea, Israel). Endothelial 
function as assessed by reactive hyperemic index (RHI) 
has previously been described [20]. Briefly, a designed 
probe is placed bilaterally on each index finger. Follow-
ing automatic expansion of the finger probe cuff, distal 
digit volume changes are calculated from pressure altera-
tions through pressure transducers connected to the 
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EndoPAT2000 device. RHI is calculated automatically 
as the ratio between the generated signals 5-min post 
forearm occlusion and at baseline, in relationship to the 
response in the contralateral arm.
Laboratory analyses
Blood samples were collected after an overnight fast. The 
biochemical analyses were performed using commer-
cially available kits according to the manufacturers’ pro-
tocols; serum triglycerides and total cholesterol (Roche 
Diagnostics GMBH, Mannheim, Germany), direct high 
density lipoprotein (HDL) cholesterol (Horiba ABX, 
France), Apolipoprotein A1, Apolipoprotein B (DakoCy-
tomation, Glostrup, Denmark) and serum insulin (Mil-
lipore Corporation, USA). Plasma glucose was measured 
using a photometric method and HbA1c by HPLC at the 
department of Clinical Chemistry, Sahlgrenska Univer-
sity Hospital, Gothenburg. Impaired glucose homeosta-
sis, assessed by HOMA-IR was calculated to estimate 
insulin resistance using the formula: fasting serum insu-
lin (mU/L) × fasting plasma glucose (mmol/L)/22.5 [21]. 
A number of cardiovascular associated biomarkers (stem 
cell factor, vascular endothelial growth factor D (VEGF-
D), vascular endothelial growth factor A (VEGF-A), 
interleukin-6 (IL-6), and endothelial cell-specific mol-
ecule 1 also known as endocan were analyzed using the 
Olink Bioscience (Uppsala, Sweden) Proseek Multiplex 
CVD I 96 × 96 according to the manufacturer’s instruc-
tions [22]. All Proseek data are presented as arbitrary 
units (AU) in log2 values.
Follow‑up and definitions of outcome measures
Follow-up was accomplished by a physician by telephone 
interviews and confirmed through patient’s medical 
record and/or the Swedish National Board of Health’s 
Registry and median follow-up time was 5.1 years (range: 
4.4–6.2  years). Study endpoint was event-free survival 
and events were defined as the incidence of all-cause 
mortality, nonfatal stroke, nonfatal MI and coronary 
arterial revascularizations (either coronary artery bypass 
grafting or percutaneous coronary intervention). Time 
to most severe event was analyzed and ranged as follows 
death  >  MI/stroke  >  arterial revascularization. Defini-
tion of MI was clinically diagnosed by presence of persis-
tent chest pain and confirmed by pathological troponin 
dynamics and/or electrocardiogram changes. The occur-
rence of stroke was defined as focal or global neurological 
deficits lasting for more than 24 h and verified clinically 
Fig. 1 A flow‑scheme illustrating the patient recruitment process
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by a neurologist and/or by computed tomography brain 
scan.
Samples and gene expression analysis on patients 
without myocardial perfusion defects
Extraction of RNA was done on whole blood samples 
collected using Paxgene tubes from a subset of 54 con-
secutive patients without myocardial perfusion defects, 
in conjunction to the imaging procedure. Affymetrix 
Gene Arrays (Human Gene 1.0 ST array) was used to 
interrogate 28,869 transcript clusters and CEL files 
were imported to Partek Genomics Suite version 6.5 
(Partek Inc., MO, USA). The data was log2-transformed 
and Robust Multi-array Average normalization was per-
formed using ArrayStudio (Omicsoft, version 3.2.0 and 
3.5.0). The normalized gene expression values were then 
fitted with a linear regression model using the Biocon-
ductor R package ‘limma’ (linear models for microar-
ray data) version 3.22.7. Using an empirical Bayesian 
approach, the ‘limma’ package infers differential expres-
sion in individual genes from the microarray data [23].
Partial least squares—discriminant analysis, functional 
and pathway analysis
The application of partial least squares—discriminant 
analysis (PLS-DA) to the microarray data of the 54 
patient samples was carried out using the MATLAB® 
software v. 8.3.0.532 (R2012a, The MathWorks, Inc.) 
and the MATLAB® PLS Toolbox v. 7.5.2 (Eigenvector 
Research, Inc.). PLS-DA scores and weights plot were 
used to identify markers, from the ‘limma’ gene expres-
sion analysis results, correlated to patients with high 
HOMA-IR (cut-off value of median of HOMA-IR >3.1); 
and correlated to patients with decreased endothelial 
function (low RHI based on RHI median of <1.91). The 
PLS-DA scores plot based on the cut-offs for HOMA-
IR and RHI levels showed discrimination of the patient 
samples into two classes; and the weights plot for the 
appropriate latent variables revealed which genes were 
important in separating the classes and hence association 
to the appropriate class (data not shown).
To define genes associated to high HOMA-IR, and low 
RHI; and identify the biological mechanisms, pathways 
and functions co-regulated by the genes, core analyses 
were performed using the ingenuity pathway analysis 
(IPA) software (Ingenuity Systems, Redwood City, CA). 
The significance of the connection between the expres-
sion data and the canonical pathway were calculated by 
ratio and/or Fisher’s exact test. Significant genes passing 
the test criterion (e.g., t test, correlation analysis p-value 
for ANOVA or fold change) were functionally catego-
rized by gene ontology [24]. This resulted into associated 
genetic networks, canonical pathways, and biological 
functions enriched by the genes. Comparison analysis in 
IPA for the core analysis results was then carried out to 
identify co-regulated pathways.
Statistics
Deviations in sample size for the various statistical analy-
ses were due to differences in the availability of RHI, as 
well as missing values in some analyzed biomarkers. All 
analyses were performed in SPSS, (version 21.0, Chi-
cago Inc, USA). P-values of less than 0.05 were consid-
ered significant (2-tailed). Due to there is no present 
“golden standard” cut of value for HOMA-IR, we used 
the median value. We calculated the sample size based 
on the Cox PH one-sided superiority formula. With an 
overall event rate 20 %, an alpha level 5 and 80 % power, 
we need approximately 260 patients to estimate a haz-
ard ratio (HR) of 2. Sub-analyses were performed in 
patients with and without myocardial perfusion defects, 
defined as above. Values are displayed as mean  ±  SD 
for continuous variables and frequency and percentages 
for categorical variables. The test of skewness was used 
to assess normal distribution. Non-normally distributed 
variables are presented with their median and interquar-
tile range. Differences among continuous variables were 
analyzed using unpaired t test or Mann–Whitney U test, 
as appropriate. Categorical data was analyzed by Pearson 
Chi square test. Spearman’s correlation coefficients were 
used to examine relationships between continuous vari-
ables. Continuous and categorical HOMA-IR, divided by 
the median value was used in a linear regression model, 
predicting continuous RHI in patients without myocar-
dial perfusion defects. Possible co-linearity between the 
independent variables was tested using Spearman cor-
relation coefficient test and a coefficient >0.7 was con-
sidered significant. High co-linearity was found between 
fasting glucose levels and pre-diabetes diagnosis (corre-
lation coefficient 0.8). The latter was added to the mul-
tivariable model investigating factors of importance for 
outcome. The multivariable linear regression model was 
adjusted for categorical HOMA-IR median and other rel-
evant independent parameters associated to the depend-
ent parameter with a p < 0.25 (gender, previously known 
CAD, body mass index and HDL). Results are displayed 
as β-values and 95 % confidence intervals (CI). Kaplan–
Meier curves are used to display survival rates. HR and 
95  % CIs were analyzed by univariate Cox regression 
with continuous and categorical HOMA-IR, divided by 
the median value in the whole population as well as in 
patients with and without myocardial perfusion defects. 
Also multivariable COX regression analyses were per-
formed with HOMA-IR as a categorical variable divided 
by the median value, adjusted for age, body mass index, 
gender, systolic blood pressure, HDL and previously 
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known CAD, selected based on their observed relevance 
to the dependent parameter (univariate Cox regression, 
p < 0.25) in the current study.
Results
Demographic and clinical characteristics
Demographic data of the 365 non-diabetic patients with 
suspected myocardial ischemia are shown in Table  1. 
HbA1c levels were normally distributed within the 
range 4.3-6.5  % (24–48  mmol/mol), of which 4 subjects 
are above the 95:th percentile, normal range 4.6–6.4  % 
(27–46  mmol/mol) as by local definition (Department 
of Clinical Chemistry, Sahlgrenska University Hospi-
tal, Gothenburg, Sweden). Fasting serum insulin lev-
els showed a right skewed distribution with the range 
28–493 pmol/L. Fasting plasma glucose levels were nor-
mally distributed with the range 4.0–6.8  mmol/L. Also 
HOMA-IR showed a right skewed distribution with the 
range 1.1–14.0. Among the 365 patients, 116 subjects 
(32 %) were found to have impaired fasting glucose levels 
(100–125 mg/dL; 5.6–6.9 mmol/L) as defined by Ameri-
can Diabetes Association. Impaired fasting glucose levels 
(≥5.6 mmol/L) was used to define patients with pre-dia-
betes in subsequent analyses.
HOMA‑IR as predictor of clinical outcome
The median follow-up time in our study was 62 months 
(5.1  years) with a range of 53–74  months. There was 
no loss to follow-up. The occurrence of events during 
the follow-up time in the study population was 21  % 
(death n  =  15, MI/stroke n  =  15, coronary revascu-
larization n  =  52). In a univariate analysis continuous 
HOMA-IR (HR: 1.13, CI: 1.04–1.24, p = 0.005, χ2: 7.9) 
predicted event-free survival. Furthermore, in a uni-
variate survival analysis (Table  2) HOMA-IR (χ2: 17.1) 
above median value significantly predicted outcome 
together with age (χ2: 15.3), previously known CAD (χ2: 
30.6), gender (χ2: 23.6), HDL (χ2: 7.7) and systolic blood 
pressure (χ2: 4.4). In a multivariable model of survival 
analysis (Table  2) adjusting for relevant risk factors 
(p  <  0.001, χ2: 55.0), HOMA-IR above median inde-
pendently predicted outcome (Fig.  2a) together with 
age, previously known CAD and gender. Also when 
adding pre-diabetes (univariate survival analysis: HR: 
1.7, CI: 1.1–2.7, p = 0.020, χ2: 5.5) to the multivariable 
model, HOMA-IR above median (HR: 1.8, CI: 1.1–3.2, 
p = 0.042, χ2: 55.1) but not pre-diabetes (HR: 1.05, CI: 
1.7, p =  0.854, χ2: 55.1) remained an independent pre-
dictor of outcome.
Table 1 Baseline characteristics of study cohort
Values are displayed as mean ± SD or median and interquartile range for continuous variables and frequency and percentages for categorical variables
ApoA apolipoprotein A, ApoB apolipoprotein B, HbA1c glycosylated hemoglobin, HDL high density lipoprotein cholesterol. MI myocardial infarction, Known CAD 
previously known coronary artery disease, RHI reactive hyperemic index
Whole study population (n = 365) Without perfusion defects (n = 238)
Age (years) 62 ± 9 61 ± 9
Women 202 (55 %) 150 (63 %)
Body mass index 25.7 ± 3.5 25.4 ± 3.5
Current smoker 47 (13 %) 31 (13 %)
Family history of CAD 142 (39 %) 89 (37 %)
ACE‑inhibitors 69 (19 %) 32 (13 %)
Beta‑blockers 173 (47 %) 96 (40 %)
Statins 146 (40 %) 83 (35 %)
Aspirin 178 (49 %) 102 (43 %)
Systolic blood pressure (mmHg) 144 ± 23 144 ± 22
Known CAD 94 (26 %) 44 (18 %)
Previous MI 51 (14 %) 19 (8 %)
Triglycerides (mmol/L) (n = 362) 1.2 (0.8–1.6) 1.1 (0.8–1.3) (n = 235)
Cholesterol (mmol/L) (n = 360) 5.4 ± 1.3 5.4 ± 1.1 (n = 234)
HDL (mmol/L) 1.47 (1.24–1.72) 1.49 (1.29–1.75)
ApoB/ApoA1 0.64 (0.53–0.79) 0.62 (0.52–0.76)
Fasting glucose (mmol/L) 5.3 ± 0.5 5.3 ± 0.5
Insulin (pmol/L) 94 (69–125) 92 (69–122)
HbA1c (mmol/mol, %) 36.6 ± 3.8 (5.5 ± 0.3 %) 36.2 ± 3.5 (5.5 ± 0.32 %)
HOMA‑IR 3.1 (2.3–4.3) 3.1 (2.3–4.1)
RHI (n = 345) 1.89 (1.55–2.47) 1.91 (1.59–2.48) (n = 225)
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Independent prognostic value of HOMA‑IR in patients 
without myocardial perfusion defects
Impaired glucose homeostasis in the non-diabetic state 
may be of importance in progression of microvascular 
dysfunction, i.e., in patients with chest pain without 
obstructive CAD. We therefore investigated the addi-
tive value of HOMA-IR to MPS results. In our cohort, 
the 238 patients without myocardial perfusion defects 
had an event rate of 13  %, while 127 patients displayed 
myocardial perfusion defects with an event rate of 35 %. 
In patients without myocardial perfusion defects the 
difference in event rate in patients with HOMA-IR 
below versus above median was 15  % (p  =  0.001), and 
in patients with myocardial perfusion defects, the dif-
ference was 22  % (p =  0.008). Furthermore, HOMA-IR 
showed additive value for outcome when combined 
with MPS results. High versus low HOMA-IR had sig-
nificant prognostic value in patients without (HR: 3.4, 
CI: 1.5–7.5, p = 0.003, χ2: 45.0) and with myocardial per-
fusion defects (HR: 2.1, CI: 1.4–4.0, p = 0.018, χ2: 45.0). 
In the multivariable model including conventional risk 
factors (age, gender, systolic blood pressure, body mass 
index, HDL and previously known CAD (p  <  0.001, χ2: 
71.1), HOMA-IR showed independent prognostic value 
in patients without myocardial perfusion defects (HR: 
2.7, CI: 1.2–6.3, p = 0.02), but not in patients with myo-
cardial perfusion defects (HR: 1.7, CI: 0.3–1.2, p = 0.14) 
Table 2 Univariate and  multivariable adjustment 
of HOMA-IR as predictor of clinical outcome
Survival analyses on the whole study population of non-diabetic patients with 
suspected myocardial ischemia. Data are presented with hazard ratio and 95 % 
CI, (n = 365)
CI confidence interval, HDL high density lipoprotein cholesterol, HR hazard ratio 
Known CAD previously known coronary artery disease
Univariate model Multivariable model
HR (95 % CI) p value HR (95 % CI) p value
Age 1.05 (1.03–1.08) <0.001 1.04 (1.01–1.07) 0.007
Known CAD 3.27 (2.10–5.10) <0.001 1.87 (1.15–3.05) 0.012
Gender 3.10 (1.92–5.01) <0.001 1.92 (1.11–3.35) 0.020
HOMA‑IR above 
median
2.72 (1.70–4.46) <0.001 1.88 (1.09–3.26) 0.023
HDL 0.38 (0.19–0.75) 0.005 0.82 (0.41–1.63) 0.570
 Systolic blood 
pressure
1.01 (1.00–1.02) 0.036 1.00 (0.99–1.01) 0.693
Body mass index 1.05 (0.99–1.12) 0.120 1.00 (0.92–1.08) 0.915
Fig. 2 COX regression analyses between HOMA‑IR below and above median on non‑diabetic patients with suspected myocardial ischemia 
(n = 365). In a COX regression analysis a HOMA‑IR above median provides an independent prognostic value predicting long‑term events in the 
whole study population. In a COX regression analysis b HOMA‑IR provides independent prognostic information in non‑diabetic patients with no 
myocardial perfusion defects (HR: 2.7, p = 0.02, n = 238), but not in patients with myocardial perfusion defects (HR: 1.7, p = 0.14, n = 127). Statistics 
are presented as Chi square values and HR. Gr group, HR hazard ratio
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(Fig.  2b). Importantly, HOMA-IR above median 
remained an independent predictor of outcome in 
patients without myocardial perfusion defects also when 
adding pre-diabetes (HOMA-IR HR: 2.7 CI: 1.1–6.3, 
p = 0.02) to the multivariable model (χ2: 71.2). Moreover, 
when using the first multivariable model and excluding 
the 94 patients with previously known CAD, HOMA-IR 
above median increasingly predicted outcome in patients 
without myocardial perfusion defects (HR: 5.0, CI: 1.4–
18.3, p =  0.014) alongside age (HR: 1.05, CI: 1.01–1.09, 
p  =  0.008). However, HOMA-IR had no independent 
prognostic value in patients with myocardial perfusion 
defects (HR: 1.5, CI: 0.59–3.9, p = 0.388) when patients 
with previously known CAD were excluded.
HOMA‑IR is associated with decreased peripheral 
endothelial function in patients without myocardial 
perfusion defects
Insulin resistance and endothelial dysfunction are known 
to coexist [14]. Therefore, we investigated the associa-
tion of HOMA-IR to peripheral endothelial function in 
non-diabetic patients with chest pain without myocardial 
perfusion defects. Continuous HOMA-IR displayed a 
significant negative association with RHI (β: −0.014, (CI: 
−0.023–0.004), p = 0.004). Also, patients with HOMA-IR 
in the upper compared to lower median value displayed 
a significant inverse association with RHI (Table  3) and 
we observed a significantly higher RHI value in patients 
above compared to below median value (2.2  ±  0.7 and 
1.9 ± 0.7, respectively, p = 0.001). Additionally, in a mul-
tivariable linear regression analysis (Table 3) adjusting for 
risk factors associated with RHI in our study, HOMA-IR 
above median independently predicted decreased RHI (R 
square = 0.05).
HOMA‑IR and cardiovascular biomarkers in patients 
without myocardial perfusion defects
Furthermore, we aimed to investigate the relation of 
increased HOMA-IR to inflammatory and vascular 
growth factor associated biomarkers in patients without 
myocardial perfusion defects (n = 238). The systemic low 
degree inflammation marker IL-6 showed positive corre-
lation to HOMA-IR (corr.coeff =  0.200, p =  0.002) and 
a significantly higher value in patients with HOMA-IR 
above compared to below median value (3.8  ±  1.1 and 
3.4 ±  0.9 AU, respectively, p =  0.008). The growth fac-
tor VEGF-D was inversely correlated to HOMA-IR (corr.
coeff  =  −0.213, p =  0.001) and was significantly lower 
in patients with HOMA-IR above compared to lower 
median value (6.3 ± 0.3 and 6.1 ± 0.4 AU, below versus 
above median, respectively, p = 0.04). Reduced levels of 
VEGF related factor endocan also called the endothelial 
cell-specific molecule 1 was further associated with high 
HOMA-IR (corr.coeff = −0.249, p < 0.001) and lower in 
patients with HOMA-IR above median (2.5  ±  0.3 and 
2.3 ±  0.3 AU, below versus above median, respectively, 
p  =  0.006). We observed positive correlation between 
VEGF-D and endocan (corr.coeff  =  0.375, p  <  0.001), 
which confirmed the relationship suggested in previ-
ous studies [25]. However, no significant correlation 
was found between VEGF-A and HOMA-IR (corr.
coeff  =  0.062, p  =  0.34) and no difference was found 
between VEGF-A in patients with HOMA-IR above 
compared to below median (9.0  ±  0.4 and 9.0  ±  0.3, 
respectively). Furthermore, high HOMA-IR was inversely 
correlated with Stem cell factor (corr.coeff  =  −0.219, 
p  =  0.001) and patients with HOMA-IR above median 
had reduced level of Stem cell factor (8.1  ±  0.4 and 
8.0 ±  0.3 AU, below versus above median, respectively, 
p = 0.001).
Gene Expression, PLS‑DA and pathway analyses in patients 
with high HOMA‑IR and low RHI
The outcome of ‘limma’ gene expression analysis is mod-
erated t-statistics with Bayesian-adjusted denominators 
that incorporate information across all genes [26]. The 
‘limma’ result consisting of the probeset IDs and the 
log-fold expression values of gene transcripts were then 
analyzed using the IPA software. Differential expressed 
genes were characterized having an estimated fold-
change >1.5, and the Benjamini and Hochberg’s method 
was used to control false discovery rate smaller than 
0.05 [27]. Further analysis by PLS-DA produced lists of 
gene transcripts associated to HOMA-IR above median 
and RHI below median. Thereafter, we examined the 
canonical pathways enriched. IPA comparison analysis 
gene transcripts predict patients with high HOMA-IR 
and low RHI co-regulated signaling pathways. Worth 
Table 3 Univariate and  multivariable parameters associ-
ated to reactive hyperemic index in patients without myo-
cardial perfusion defects
Linear regression analyses on non-diabetic patients without myocardial 
perfusion defects (n = 225)
CI confidence interval, HDL high density lipoprotein cholesterol, Known CAD 
previously known coronary artery disease
Univariate Multivariable model
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mentioning is the activated pro-inflammatory pathways, 
dendritic cell maturation signaling, nuclear factor kappa 
B signaling and toll-like receptor signaling as well as 
inhibited eukaryotic initiation factor 2 (EIF2) signaling 
(Fig. 3).
Discussion
We show how elevated HOMA-IR, a marker of insulin 
resistance [28], independently predicts outcome in non-
diabetic patients with chest pain symptoms and sus-
pected myocardial ischemia. Importantly, HOMA-IR has 
independent prognostic value in patients without myo-
cardial perfusion defects and in this subgroup increased 
HOMA-IR was associated with decreased endothelial 
function. Furthermore, in patients without myocardial 
perfusion defects increased HOMA-IR was associated 
with increased circulating levels of IL-6 and decreased 
levels of vascular growth factors, suggesting systemic 
inflammation and impaired angiogenic potential. In sup-
port to the protein level data, global gene expression 
analysis revealed that co-regulated pro-inflammatory 
pathways and down-regulated EIF2 signaling pathway 
were associated with high HOMA-IR and impaired 
endothelial function.
HOMA‑IR as predictor of clinical outcome
MPS is a well-established tool in detecting hemo-
dynamically significant obstructive CAD and has 
strong prognostic value [2]. However MPS may not 
be the optimal modality to detect global microvascu-
lar dysfunction, which typically requires absolute flow 
reserve quantification [29]. In the current non-diabetic 
population, increased insulin resistance as measured 
by HOMA-IR predicted future events. Interestingly, 
an independent prognostic value of HOMA-IR was 
only observed in patients without myocardial perfu-
sion defects. In line with previous reports, patients 
with perfusion defects may already be at high risk 
for cardiovascular events, so testing HOMA-IR may 
not add independent values for prognostic evaluation 
[11]. The fact that an independent prognostic value 
of HOMA-IR was observed in non-diabetic patients 
without myocardial perfusion defects independently 
of pre-diabetes, supported our hypothesis that insu-
lin resistance could be one of the main mechanisms 
associated with increased cardiovascular risk in these 
patients. Further, assessing HOMA-IR may add clinical 
value also in patients with long standing type 2 diabe-
tes. Srinivasan et  al. recently showed that HOMA-IR 
below 2.5 is associated with normal coronary angio-
gram indicating importance of assessing insulin resist-
ance also to help to predict outcome in type 2 diabetes 
patients [30].
HOMA‑IR and peripheral endothelial function
The results of the present study indicate that insulin 
resistance is associated with peripheral endothelial dys-
function and predicts clinical outcome also in patients 
without myocardial perfusion defects. It was recently 
shown that the prevalence of microvascular dysfunction 
in patients with chest pain and non-obstructive CAD 
is high in both men and women and that conventional 
risk factors play a minor role [8]. In the present study, 
Fig. 3 Global gene expression pathway analysis on patients without 
myocardial perfusion defects (n = 54). Red bars predict an overall 
increase in the activity of the pathway (activation) while blue bars 
indicate a prediction of an overall decrease in activity (deactivation/
inhibition). White bars are those with a z‑score which is zero or very 
close to zero. The overall activation/inhibition (deactivation) states 
of the pathways are predicted based on a Z‑score algorithm. Z‑score 
gives a statistical measure of the relationship of up and downregu‑
lated gene transcripts in the microarray data set with‑respect‑to a 
particular pathway. This Z‑score is used to mathematically compare 
the microarray data set with the canonical pathway patterns. A path‑
way is predicted as activated or inhibited by comparing the expected 
pattern (up/downregulation of key genes in the pathway) if the path‑
way is activated against the actual pattern (up/downregulated key 
genes) in the microarray data set. If the actual pattern matches the 
expected pattern, the Z‑score is positive (Z‑score > ~2 = activated 
pathway) otherwise negative (Z‑score <2 = inhibited pathway)
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endothelial function was assessed by Endo-PAT, which 
has been shown to predict coronary endothelial dysfunc-
tion [20] as well as having additive prognostic value to 
the Framingham risk score [11]. HOMA-IR is a surro-
gate measure of insulin resistance that has been shown to 
be more strongly associated with cardiovascular disease 
than glucose or insulin concentrations alone in non-dia-
betic patients [31]. Endothelial dysfunction is a conse-
quence of different mechanisms associated with insulin 
resistance causing impaired vasodilation or increased 
vasoconstriction [12–14]. Normal insulin action results 
in vasodilation at the arterial, venous, and microcircula-
tory levels [32] via increased production of endothelial 
nitric oxide [14, 17, 32]. In accordance, insulin resistance 
has been shown to reduce the expression and function of 
the endothelial nitric oxide-synthase gene in endothelial 
cells and microvessels in insulin resistant rats [16]. Inter-
estingly, insulin resistance in apparently healthy adoles-
cents is associated with endothelial dysfunction [33]. 
Furthermore, microalbuminuria is known to correlate 
with endothelial dysfunction and has been independently 
associated with insulin resistance in type 2 diabetes and 
it was recently shown that HOMA-IR below 2.5 and 
absence of microalbuminuria is associated with beneficial 
CAD profile [30].
HOMA‑IR and angiogenic factors
The pathophysiological mechanisms underlying micro-
vascular dysfunction is multifactorial [13]. In addition 
to e.g., endothelial dysfunction, structural vascular 
adaption, including vascular remodeling, rarefaction, 
and collateralization could also play roles [13]. Ischemia 
is known to stimulate angiogenesis, and conditions of 
only minimal ischemia stimulate development of collat-
eral vessels [34]. The growth factor Stem cell factor is 
important in mobilization and recruitment of vascular 
angiogenic endothelial progenitor cells in response to 
ischemia [35]. Interestingly, decreased Stem cell factor 
levels were recently found in diabetic patients and were 
related to incidence of cardiovascular events [19]. In our 
study, decreased Stem cell factor correlated significantly 
to high HOMA-IR and decreased VEGF-D levels (data 
not shown). VEGF-D has been shown to be impor-
tant for vascular angiogenesis and lymphangiogenesis, 
as well as stimulating endothelial production of nitric 
oxide [36, 37]. In the current study increased HOMA-
IR was inversely correlated to VEGF-D at a protein 
level. We further demonstrate that VEGF-D correlates 
positively to endocan, which is known to be induced 
by VEGF and involved in tumor angiogenesis [25]. In 
line with our data, He et al. showed that reduced PI3K/
Akt signaling is likely responsible for the reduction in 
VEGF induced vascularization in the myocardium at 
both basal and ischemic states [18]. Furthermore, Bon-
ner et al. showed that deletion of VEGF in murine car-
diac muscle induced capillary rarefaction and promoted 
insulin resistance [38]. Taken together, these studies 
indicate that insulin resistance might promote down-
regulation of VEGF, causing vascular rarefaction which 
may accelerate further development of insulin resistance 
due to insufficient delivery of insulin. Ischemia-induced 
hypoxia is also a trigger for increased transcription and 
translation of vascular endothelial growth factors [34] 
ultimately leading to angiogenesis. The current study 
displayed impaired EIF2 pathway to be associated with 
insulin resistance and endothelial dysfunction. Since 
VEGF mRNA translation is dependent on the EIF2 
pathway, especially during hypoxia [39], an impaired 
EIF2 pathway could at least in part be responsible for 
the low VEGF-D protein levels associated with high 
HOMA-IR. In addition, it was recently reported a novel 
VEGF signaling mechanism involving the EIF2 pathway 
to activate the unfolded protein response in endothelial 
cells [40], which seems to be important for angiogenesis 
and cell survival. Thus, a down-regulated EIF2 pathway 
may further diminish the action of VEGF on the vascu-
lar wall. Taken together, the reduced levels of VEGF-D 
and Stem cell factor could be mechanisms underlying 
endothelial dysfunction associated with insulin resist-
ance in this patient population.
HOMA‑IR and subclinical inflammation
A large proportion of the study population was pre-
diabetes patients. The pre-diabetic state is associated 
with increased systemic inflammation [41] and IL-6 has 
been shown to be related to coronary microvascular dys-
function [42]. We demonstrated that high HOMA-IR 
was associated with increased levels of IL-6 also in this 
cohort, which is in line with previous findings that obese, 
non-diabetic insulin resistant patients have elevated 
IL-6 levels [43]. Interestingly, Antoniades et  al. showed 
increased IL-6 levels in healthy subjects to be associated 
with impaired peripheral flow-mediated vasodilation and 
to increased levels of asymmetrical dimethylarginine, an 
endogenous inhibitor of endothelial nitric oxide synthase 
[44]. In line with these results, IL-6 was demonstrated to 
inhibit endothelium-dependent nitric oxide-mediated 
relaxation and enhance contraction in an experimental 
model [45], which suggests a direct role of IL-6 in micro-
vascular dysfunction associated with insulin resistance. 
In accordance, gene expression and pathway analysis 
indicated upregulation of multiple pro-inflammatory 
pathways including dendritic cell maturation signal-
ing pathway and pattern recognition receptors signaling 
pathway, which both could result in e.g., increased sys-
temic levels of IL-6.
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Study limitations
Despite extensive biomarker analysis several other 
important markers for cardiovascular risk may still be 
missing, such as adiponectin [46–48] and microalbumi-
nuria [30]. Global gene expression pathway analysis was 
performed on RNA extracted from whole blood cells, 
used as a surrogate cell compartment mirroring similar 
biological processes in other relevant tissues. Caution 
should be taken when extrapolating the finding to other 
target tissues, such as endothelial cells. Further, more 
studies are warranted to investigate mechanistic rele-
vance in other populations. Finally, the current study is 
still of limited size and therefore caution should be taken 
when interpreting the data.
Conclusions
Our study shows that pre-diabetes as indicated by 
impaired glucose homeostasis is prevalent in non-dia-
betic patients with chest pain and suspected myocar-
dial ischemia. Elevated HOMA-IR is associated with 
decreased endothelial function, and adds independent 
prognostic information in patients without myocardial 
perfusion defects. Furthermore, our results also indi-
cate that increased systemic low degree inflammation 
and decreased vascular growth factor production may 
be underlying mechanisms connecting insulin resist-
ance with microvascular dysfunction in this patient 
population.
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